| 8.69 -0.06 (-0.69%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.53 | 1-year : | 13.47 |
| Resists | First : | 9.88 | Second : | 11.53 |
| Pivot price | 9.06 |
|||
| Supports | First : | 7.9 | Second : | 6.69 |
| MAs | MA(5) : | 9.13 |
MA(20) : | 8.64 |
| MA(100) : | 7.34 |
MA(250) : | 5.23 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 59.5 |
D(3) : | 71.2 |
| RSI | RSI(14): 53.9 |
|||
| 52-week | High : | 9.88 | Low : | 2.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FULC ] has closed above bottom band by 27.6%. Bollinger Bands are 5.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.81 - 8.87 | 8.87 - 8.92 |
| Low: | 8.32 - 8.4 | 8.4 - 8.46 |
| Close: | 8.57 - 8.69 | 8.69 - 8.77 |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fri, 10 Oct 2025
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fri, 10 Oct 2025
FULC - Fulcrum Therapeutics Latest Stock News & Market Updates - Stock Titan
Fri, 26 Sep 2025
Pociredir Trial And DBA IND Filing Put Fulcrum Therapeutics On Watchlist - RTTNews
Thu, 25 Sep 2025
We're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 101.4 (%) |
| Shares Short | 3,350 (K) |
| Shares Short P.Month | 3,720 (K) |
| EPS | -1.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.8 % |
| Return on Equity (ttm) | -30 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.98 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -65 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -7.37 |
| PEG Ratio | 0 |
| Price to Book value | 2.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|